Literature DB >> 10424842

Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori.

D J Pasta1, J L Taylor, J M Henning.   

Abstract

Decision-analytic models are frequently used to evaluate the relative costs and benefits of alternative therapeutic strategies for health care. Various types of sensitivity analysis are used to evaluate the uncertainty inherent in the models. Although probabilistic sensitivity analysis is more difficult theoretically and computationally, the results can be much more powerful and useful than deterministic sensitivity analysis. The authors show how a Monte Carlo simulation can be implemented using standard software to perform a probabilistic sensitivity analysis incorporating the bootstrap. The method is applied to a decision-analytic model evaluating the cost-effectiveness of Helicobacter pylori eradication. The necessary steps are straightforward and are described in detail. The use of the bootstrap avoids certain difficulties encountered with theoretical distributions. The probabilistic sensitivity analysis provided insights into the decision-analytic model beyond the traditional base-case and deterministic sensitivity analyses and should become the standard method for assessing sensitivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424842     DOI: 10.1177/0272989X9901900314

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  8 in total

1.  Cost-effectiveness of automated external defibrillator deployment in selected public locations.

Authors:  Peter Cram; Sandeep Vijan; A Mark Fendrick
Journal:  J Gen Intern Med       Date:  2003-09       Impact factor: 5.128

Review 2.  Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.

Authors:  Rahul Jain; Michael Grabner; Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

3.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.

Authors:  Thomas E Delea; Paul Tappenden; Oleg Sofrygin; Dominy Browning; Mayur M Amonkar; Jon Karnon; Mel D Walker; David Cameron
Journal:  Eur J Health Econ       Date:  2011-06-24

5.  Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs.

Authors:  F Peris; E Martínez; X Badia; M Brosa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture.

Authors:  K Zarca; I Durand-Zaleski; C Roux; J-C Souberbielle; A-M Schott; T Thomas; P Fardellone; C-L Benhamou
Journal:  Osteoporos Int       Date:  2014-04-02       Impact factor: 4.507

7.  Evaluation of long-term clinical and health service outcomes following coronary artery revascularisation in Western Australia (WACARP): a population-based cohort study protocol.

Authors:  C Gardner; J M Rankin; E Geelhoed; M Nguyen; M Newman; D Cutlip; M W Knuiman; T G Briffa; M S T Hobbs; F M Sanfilippo
Journal:  BMJ Open       Date:  2014-10-03       Impact factor: 2.692

8.  Cost-effectiveness of habit-based advice for weight control versus usual care in general practice in the Ten Top Tips (10TT) trial: economic evaluation based on a randomised controlled trial.

Authors:  Nishma Patel; Rebecca J Beeken; Baptiste Leurent; Rumana Z Omar; Irwin Nazareth; Stephen Morris
Journal:  BMJ Open       Date:  2018-08-13       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.